Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study

Summary Background In most countries, alteplase given within 4·5 h of onset is the only approved medical treatment for acute ischaemic stroke. The newer thrombolytic drug tenecteplase has been investigated in one randomised trial up to 3 h after stroke and in another trial up to 6 h after stroke in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology 2015-04, Vol.14 (4), p.368-376
Hauptverfasser:	Huang, Xuya, MRCP, Cheripelli, Bharath Kumar, MRCP, Lloyd, Suzanne M, MSc, Kalladka, Dheeraj, MRCP, Moreton, Fiona Catherine, MRCP, Siddiqui, Aslam, FRCR, Ford, Ian, PhD, Muir, Keith W, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Brain Ischemia - complications Brain Ischemia - diagnosis Brain Ischemia - drug therapy Cerebral Angiography Cerebral Hemorrhage - chemically induced Drug Administration Schedule Drug dosages Drug therapy Female Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - adverse effects Fibrinolytic Agents - therapeutic use Heart attacks Humans Incidence Infusions, Intravenous Injections, Intravenous Male Medical imaging Middle Aged Mortality Neurology Pain Perfusion Imaging Population Prospective Studies Single-Blind Method Stroke Stroke - diagnosis Stroke - drug therapy Stroke - etiology Tenecteplase Thrombolytic Therapy - methods Time Factors Tissue Plasminogen Activator - administration & dosage Tissue Plasminogen Activator - adverse effects Tissue Plasminogen Activator - therapeutic use Tomography, X-Ray Computed - methods Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!